Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice

Martina Schweiger, Matthias Romauch,, Renate Schreiber, Gernot Grabner, Sabrina Hütter, Petra Kotzbeck, Pia Benedikt, Thomas O. Eichmann, Sohsuke Yamada, Oskar Knittelfelder, Clemens Diwoky, Carina Julia Doler, Nicole Mayer, Werner De Cocco, Rolf Breinbauer, Robert Zimmermann, Rudolf Zechner

Research output: Contribution to journalArticle

Abstract

Elevated circulating fatty acids (FAs) contribute to the development of obesity-associated metabolic complications such as insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). Hence, reducing adipose tissue lipolysis to diminish the mobilization of FAs and lower their respective plasma concentrations represents a potential treatment strategy to counteract obesity-associated disorders. Here we show that specific inhibition of adipose triglyceride lipase (Atgl) with the chemical inhibitor, Atglistatin, effectively reduces adipose tissue lipolysis, weight gain, IR and NAFLD in mice fed a high-fat diet. Importantly, even long-term treatment does not lead to lipid accumulation in ectopic tissues such as the skeletal muscle or heart. Thus, the severe cardiac steatosis and cardiomyopathy that is observed in genetic models of Atgl deficiency does not occur in Atglistatin-treated mice. Our data validate the pharmacological inhibition of Atgl as a potentially powerful therapeutic strategy to treat obesity and associated metabolic disorders.
Original languageEnglish
Article number14859
Number of pages14
JournalNature Communications
Volume8
DOIs
Publication statusPublished - 2017

Fields of Expertise

  • Human- & Biotechnology

Fingerprint Dive into the research topics of 'Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice'. Together they form a unique fingerprint.

Cite this